Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Blood (2024) 144 (Supplement 1): 229.

https://doi.org/10.1182/blood-2024-204606

Published: 2024

Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Blood (2024) 144 (Supplement 1): 235.

https://doi.org/10.1182/blood-2024-199710

Published: 2024

Journal Articles

Bendamustine Plus Brentuximab Has Superior Efficacy to Brentuximab Monotherapy As Third-Line Treatment for Classical Hodgkin Lymphoma: A Real-World, Multicentre UK Analysis

Blood (2023) 142 (Supplement 1): 6173.

https://doi.org/10.1182/blood-2023-186601

Published: 2023

Journal Articles

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Blood (2022) 140 (Supplement 1): 1770–1772.

https://doi.org/10.1182/blood-2022-159976

Published: 2022

Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson

Blood (2022) 140 (Supplement 1): 9478–9479.

https://doi.org/10.1182/blood-2022-163499

Published: 2022

Journal Articles

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Joanna Hack, Inês Ralha, Sam Wilding, Louise Stanton, Josh Caddy, Sharon Barrans, Christoph Mamot, Urban Novak, Cathy Burton, Pamela McKay, Gavin Campbell, Andrew Davies, Peter Johnson

Blood (2022) 140 (Supplement 1): 6648–6649.

https://doi.org/10.1182/blood-2022-159442

Published: 2022

Journal Articles

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Stephen Booth, Eliza Hawkes, Amy A Kirkwood, Sally F Barrington, Patrick G. Medd, Pamela McKay, Ruth Pettengell, Sunil Iyengar, Fiona Miall, John Radford, Cathy Burton, Amit Sud, Nimish Shah, Andrew M Scott, Arzhang Ardavan, Michael Northend, Laura Clifton-Hadley, Richard Jenner, Graham P. Collins

Blood (2021) 138 (Supplement 1): 2470.

https://doi.org/10.1182/blood-2021-145189

Published: 2021

Journal Articles

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew Davies, Josh Caddy, Katy Mercer, Geoff N Saunders, Louise Stanton, Graham P. Collins, MD DPhil, Thomas E C Cummin, MRCP MBBCh BSc, Anna Schuh, MD MRCP, PhD, Kirit M. Ardeshna, Andrew McMillan, John A. Radford, MD FMedSci, David John Lewis, MD, Adam Coleman, Gareth Griffiths, Cathy Burton, MBBChir, MA, MD FRCPath, Sharon Barrans, Peter Johnson, MD FRCP

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134546

Published: 2020

Journal Articles

Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

Kim M Linton, MBChB, PhD, Joanna M Oladipo, PhD, Nicholas Counsell, MSc, Janet Taylor, PhD, Cathy Burton, MBBChir, MA, MD FRCPath, Rachel Oakley, PhD, Joanna Williams, PhD, Sally F Barrington, Prof, MD PhD, Richard Byers, BSc, MSc, MBChB, PhD FRCPath, Timothy Illidge, MDPhD, John A. Radford, MD FMedSci

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136318

Published: 2020

Journal Articles

Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134972

Published: 2020

Journal Articles

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

Stuart E. Lacy, Sharon L. Barrans, Philip A. Beer, Daniel Painter, Alexandra G. Smith, Eve Roman, Susanna L. Cooke, Camilo Ruiz, Paul Glover, Suzan J. L. Van Hoppe, Nichola Webster, Peter J. Campbell, Reuben M. Tooze, Russell Patmore, Cathy Burton, Simon Crouch, Daniel J. Hodson

Blood (2020) 135 (20): 1759–1771.

https://doi.org/10.1182/blood.2019003535

Published: 2020

Includes: Supplemental data

Journal Articles

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Xiang Li, Rachel Kositsky, Anupama Reddy, PhD, Cassandra Love, Kikkeri Naresh, Jean L. Koff, MD, Ilja Nystrand, Sirpa Leppä, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Johannes Dunkel, Panu Kovanen, MD PhD, Qiu Qin, Govind Bhagat, MD, Rebecca J Leeman-Neill, MDPhD, Rashmi S. Goswami, MD PhD, Sarah Wildeman, Jan Delabie, MDPhD, Richard Burack, MD PhD, Andrew G Evans, MD PhD, Catalina Amador, MD, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, MD, Jie Xu, C. Cameron Yin, MD PhD, Anne Ortved Gang, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Jason Yongsheng Chan, MBBS, MRCP, Daryl Ming Zhe Cheah, Shin Yeu Ong, MD FRCPath, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Magdalena Czader, MD PhD, Lin Wang, PhD, Amber Landis, Michael C. Churnetski, David L. Jaye, MD, Christopher R. Flowers, MD MS, Chad M. McCall, MD PhD, Jadee Neff, MD PhD, Matthew S. McKinney, MD, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, MD, Agata M. Bogusz, MDPhD, Andrea Stafford Hintz, HSLT, Alexandra E. Kovach, MD, Nishitha Reddy, MD, Mary Ann Thompson Arildsen, MD PhD, Emily F Mason, MD PhD, Ridas Juskevicius, MD, William Choi, MBBS,MRCP, Rex Au-Yeung, Eric Tse, MBBS, PhD FRCP, FRCPath, Vincent Sarno, Amy Chadburn, MD, Rafael Lopez, MD, Jennifer R Chapman, MD, Amir Behdad, MD, Neta Goldschmidt, MD, John Goodlad, MD, Cathy Burton, Raju Pillai, MD, Abner Louissaint, Jr., MD PhD, Dina Sameh Soliman, MD MB, MMSc, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 19.

https://doi.org/10.1182/blood-2019-130255

Published: 2019

Journal Articles

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Nicolas Martinez-Calle, MD MSc, Amy A. Kirkwood, MSc, Maxine Lamb, PhD, Alexandra Smith, PhD, Kate Manos, Caroline Shrubsole, MD, Nicola Gray, Sapna Ladani, MRCP, Katharine Louise Lewis, BMBS, FRCPath, MRCPath, Mark Bishton, Matthew J Ahearne, MDMBBS, Eliza A Hawkes, Wendy Osborne, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Cathy Burton, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD

Blood (2019) 134 (Supplement_1): 2849.

https://doi.org/10.1182/blood-2019-122083

Published: 2019

Journal Articles

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Blood (2019) 134 (Supplement_1): 2769.

https://doi.org/10.1182/blood-2019-124352

Published: 2019

Journal Articles

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Blood (2018) 132 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2018-99-116750

Published: 2018

Journal Articles

Does Life-Expectancy in Patients with Diffuse Large B-Cell Lymphoma Return to Normal? Findings from a UK-Based Population-Based Study

Russell Patmore, FRCPath, Alexandra Smith, PhD, Han-I Wang, PhD, Maxine Lamb, PhD, Debra Howell, PhD, Cathy Burton, Eve Roman, PhD

Blood (2018) 132 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2018-99-115277

Published: 2018

Journal Articles

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Blood (2017) 130 (Supplement 1): 2734.

https://doi.org/10.1182/blood.V130.Suppl_1.2734.2734

Published: 2017

NARROW

Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Bendamustine Plus Brentuximab Has Superior Efficacy to Brentuximab Monotherapy As Third-Line Treatment for Classical Hodgkin Lymphoma: A Real-World, Multicentre UK Analysis

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Does Life-Expectancy in Patients with Diffuse Large B-Cell Lymphoma Return to Normal? Findings from a UK-Based Population-Based Study

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only